List of Excipients in Branded Drug VANRAFIA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	CROSPOVIDONE	2034-07-07
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	CYSTEINE HYDROCHLORIDE	2034-07-07
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	GLYCERYL DIBEHENATE	2034-07-07
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	HYPROMELLOSE	2034-07-07
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	LACTOSE MONOHYDRATE	2034-07-07
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	POLYETHYLENE GLYCOL	2034-07-07
Novartis Pharmaceuticals Corporation	VANRAFIA	atrasentan	0078-1420	SILICON DIOXIDE	2034-07-07

Vanrafia Excipient Strategy and Commercial Opportunities

Last updated: October 5, 2026

Vanrafia is a low-dose, once-daily oral sparsentan product for adults with primary IgA nephropathy at risk of disease progression. Its commercial excipient opportunity is less about creating a new active ingredient platform and more about controlling tablet manufacturability, dose flexibility, stability, patient acceptability, and generic substitution risk. The most valuable opportunities are low-dose content uniformity, robust film coating, moisture control, scalable direct compression, and differentiated packaging.

What is Vanrafia and how does its formulation differ from Filspari?

Vanrafia contains sparsentan, a dual endothelin A receptor and angiotensin II type 1 receptor antagonist. Filspari is the higher-dose sparsentan product marketed by Travere Therapeutics. Vanrafia uses a lower-dose formulation intended for IgA nephropathy treatment.

Attribute	Vanrafia	Filspari
Active ingredient	Sparsentan	Sparsentan
Dosage form	Oral film-coated tablet	Oral film-coated tablet
Primary indication	Reduction of proteinuria in adults with primary IgA nephropathy at risk of disease progression	Primary IgA nephropathy
Dosing concept	Lower-dose, once-daily regimen	Higher-dose titration regimen
Developer	Travere Therapeutics	Travere Therapeutics
Key formulation issue	Dose uniformity and tablet-size optimization	High-dose drug loading and tablet robustness
Regulatory pathway	FDA-approved drug product	FDA-approved drug product

The lower strength creates a different formulation problem from Filspari. At low active-ingredient loading, excipient selection has a greater effect on blend uniformity, segregation, tablet weight, dissolution, and content uniformity. Vanrafia therefore gives excipient suppliers and contract manufacturers a potential entry point even where the active pharmaceutical ingredient and core tablet technology are established.

What excipients are used in Vanrafia tablets?

The FDA-approved product labeling identifies the inactive ingredients used in Vanrafia tablets. The formulation is expected to use conventional oral solid-dose excipients, including diluents, disintegrants, glidants, lubricants, binders, and film-coating materials. The exact grade, supplier, particle-size distribution, and quantitative composition are commercially important but are generally not disclosed in the public prescribing information.

Likely functional categories include:

Formulation function	Relevant excipient classes	Commercial purpose
Dilution and compressibility	Microcrystalline cellulose, lactose or another soluble diluent	Controls tablet weight and mechanical strength
Disintegration	Croscarmellose sodium or crospovidone	Supports immediate-release dissolution
Binding	Povidone or comparable binder	Improves granule and tablet cohesion
Flow enhancement	Colloidal silicon dioxide	Reduces blend variability and improves die filling
Lubrication	Magnesium stearate	Reduces ejection force and tooling adhesion
Film coating	Hypromellose or polyvinyl alcohol, plasticizer, titanium dioxide, talc, colorants	Protects the core and supports product identification

The strategic point is that Vanrafia’s commercial performance depends on excipient functionality rather than unusual excipient chemistry. A supplier with an equivalent compendial material may still face qualification barriers because low-dose sparsentan tablets are sensitive to particle size, surface area, density, moisture, electrostatic behavior, and mixing energy.

Which excipient attributes matter most for Vanrafia?

Low-dose content uniformity

Vanrafia’s lower strengths increase the importance of active distribution within the powder blend. The highest-value excipient attributes are:

• Narrow particle-size distribution
• Controlled bulk and tapped density
• Low electrostatic charging
• Consistent surface morphology
• Low lot-to-lot moisture variation
• Predictable lubricant adsorption
• Compatibility with the selected blending process

Direct blending may be commercially attractive, but it can create segregation risk when sparsentan and the principal diluent have materially different densities or particle sizes. Granulation can reduce segregation but adds process cost and may affect dissolution and stability.

Compressibility and tablet robustness

The excipient system must produce tablets that withstand coating, packaging, transport, and patient handling. Microcrystalline cellulose is commercially useful because it supports direct compression and can compensate for low drug loading. Lactose-based systems may improve tablet economics and dissolution but require careful control of moisture and Maillard-reactive impurities if amine-containing materials are present.

A formulation supplier can differentiate through co-processed excipients that combine a filler and disintegrant or improve flow without materially increasing tablet weight. The principal commercial test is whether the excipient reduces manufacturing variability without creating a new dissolution or stability problem.

Immediate-release dissolution

Vanrafia is intended as an oral tablet rather than a modified-release product. The disintegrant and binder balance must therefore support rapid tablet breakup and reproducible dissolution. Excessive binder or over-lubrication can slow disintegration. Excessive disintegrant can impair tablet strength or increase friability.

Excipient substitutions that preserve dissolution across commercial-scale batches have a stronger value proposition than substitutions based only on lower cost.

Moisture and chemical stability

Sparsentan stability must be assessed against water activity, temperature, light exposure, and excipient impurities. Moisture-sensitive excipient grades can increase degradation risk or alter tablet hardness during storage. Film coating and high-barrier packaging can reduce exposure, but packaging changes may be less attractive than controlling the core formulation.

Commercial opportunities include:

• Low-moisture microcrystalline cellulose
• Low-peroxide povidone
• Controlled-moisture lactose
• High-purity colloidal silicon dioxide
• Moisture-barrier film-coating systems
• Desiccant-integrated bottles and high-barrier blister systems

For a chronic nephrology product, shelf-life consistency and packaging convenience have direct commercial value because patients may take treatment for years.

What formulation patents protect Vanrafia?

Publicly available drug labels do not provide a complete picture of Vanrafia’s formulation patent estate. The core commercial protection is likely to include a combination of active-ingredient patents, pharmaceutical composition claims, treatment-method claims, and regulatory exclusivity. Excipient suppliers should not assume that use of standard compendial materials is free from infringement risk because a patent can claim a composition by functional or quantitative ranges without naming every supplier or grade.

The principal patent-screening questions are:

1. Does a patent claim sparsentan in a particular tablet composition?
2. Does it claim a specific low-dose strength or dose-escalation regimen?
3. Does it cover immediate-release dissolution parameters?
4. Does it claim a film coat, stabilizer, or moisture-control system?
5. Does it cover use in IgA nephropathy separately from other renal diseases?
6. Are any claims listed in the FDA Orange Book?
7. Are any claims pending in continuation or divisional applications?
8. Do formulation claims expire later than the active-ingredient claims?

The practical distinction is between public regulatory protection and confidential CMC know-how. A company may avoid a narrow published formulation claim but still face development delays because it lacks the reference product’s blend behavior, coating parameters, and stability data.

When does Vanrafia lose exclusivity?

Vanrafia’s commercial exclusivity has several layers:

Protection type	Business effect
New drug exclusivity	Delays certain abbreviated applications depending on the approved regulatory basis
Orphan-drug exclusivity, if granted for the relevant indication	Can restrict approval of the same drug for the same disease or condition during the exclusivity period
Listed patents	May delay approval of an ANDA or 505(b)(2) application
Method-of-use patents	May require skinny-label or carve-out strategies
Pediatric exclusivity	Can add six months to applicable exclusivity or patent terms
Trade secrets and know-how	May increase development cost without appearing in public patent records

The exact generic-entry date depends on the final Orange Book listing, patent-term adjustments, pediatric extensions, Paragraph IV litigation, and any settlement. An expiration date for a compound patent alone is not a reliable market-entry forecast.

What is the Orange Book status of Vanrafia?

Vanrafia’s Orange Book position should be analyzed at the product level rather than by relying only on the drug substance. Relevant fields include:

• NDA number
• Approved strengths
• Dosage form
• Listed patents
• Patent-use codes
• Pediatric exclusivity
• Patent expiration dates
• Delisting or correction history

Orange Book-listed method-of-use patents may allow an ANDA applicant to remove an indication while retaining approval for unpatented uses. A formulation patent with a broad claim can create a more substantial barrier because a generic applicant may need a non-infringing tablet design rather than a simple label carve-out. FDA Orange Book data and the approved Vanrafia labeling are the controlling public sources for this analysis (U.S. Food and Drug Administration, 2025a, 2025b).

What generic entry risks exist for Vanrafia?

Vanrafia is exposed to several generic development paths.

Conventional ANDA

A generic applicant could seek approval by demonstrating pharmaceutical equivalence and bioequivalence. The main development risks are low-dose content uniformity, dissolution matching, impurity control, and commercial-scale reproducibility.

505(b)(2) application

A 505(b)(2) applicant could use the approved product as a reference while pursuing a modified formulation, strength, manufacturing process, or delivery presentation. This route may be relevant for:

• Smaller tablets
• Orally disintegrating tablets
• Sprinkle formulations
• Alternative packaging
• New strength combinations
• Reduced-pill-burden regimens

Paragraph IV challenge

A Paragraph IV certification could target listed formulation, composition, or method-of-use patents. The most vulnerable claims are narrow claims that depend on conventional excipients or readily substituted quantitative ranges. Claims tied to clinical use, dosing, or specific pharmacokinetic performance may be harder to design around but can face validity and written-description challenges.

Authorized generic or license-based entry

Travere could license a generic manufacturer, launch an authorized generic, or use a supply arrangement to control post-exclusivity erosion. This strategy would be more commercially attractive if Vanrafia achieves substantial volume in chronic IgA nephropathy treatment.

Which excipient suppliers have the strongest commercial opportunities?

The best opportunities are with suppliers that can provide both material and regulatory support.

Microcrystalline cellulose and co-processed diluents

A supplier can compete on low-dose blend uniformity, direct-compression performance, low moisture, and tablet robustness. Co-processed cellulose systems may reduce development work for generic manufacturers.

Disintegrants

Croscarmellose sodium and crospovidone suppliers can differentiate through rapid disintegration at low use levels, low variability, and compatibility with the selected binder and lubricant system.

Povidone and low-peroxide binders

Low-peroxide grades can reduce oxidative stability risk. Documentation on residual impurities, elemental impurities, nitrosamines, and extractables can improve qualification prospects.

Film-coating systems

Ready-to-use film coatings can reduce process-development time and provide color and identification flexibility across strengths. The strongest opportunity is a coating system that provides moisture protection without slowing dissolution.

Packaging components

High-barrier bottles, desiccants, induction seals, and cold-form blisters can protect the product while reducing the need for an unnecessarily restrictive formulation. Packaging suppliers may gain leverage if stability studies show sensitivity to humidity.

How strong is the Vanrafia patent estate?

The patent estate should be considered moderate to strong if it combines indication protection, dosing claims, formulation claims, and regulatory exclusivity. Its practical strength depends less on the number of patents than on claim breadth and the ability of generic applicants to design around them.

Estate component	Relative defensive value
Broad sparsentan composition claims	High, if unexpired
IgA nephropathy method claims	Moderate to high
Low-dose formulation claims	Moderate
Specific excipient claims	Variable
Dissolution or pharmacokinetic claims	Moderate, depending on enforceability
Manufacturing-process claims	Moderate if process is difficult to replicate
Trade-secret CMC know-how	High operational value, limited public visibility

Standard excipients generally do not create a durable barrier by themselves. The stronger protection normally comes from the combination of active ingredient, dosage strength, therapeutic use, product profile, and regulatory exclusivity.

What licensing deals and partnerships could develop around Vanrafia?

Potential commercial structures include:

• Excipient supply agreements with dual sourcing
• Co-development agreements for a lower-cost generic formulation
• Contract manufacturing of low-dose tablets
• Authorized-generic licensing after patent expiry
• Regional commercialization rights
• Packaging partnerships for long-term chronic therapy
• Formulation licenses for pediatric or swallowing-impaired patients
• 505(b)(2) development partnerships for alternative dosage forms

For excipient companies, the most defensible arrangement is a quality-by-design partnership that links material attributes to critical tablet properties. A simple commodity supply contract provides less protection against substitution.

How does Vanrafia compare with competing IgA nephropathy products?

Vanrafia competes in a treatment market that includes targeted-release budesonide products, systemic immunosuppressive approaches, renin-angiotensin system inhibitors, and emerging complement-directed therapies. Its excipient strategy must support chronic administration, predictable dosing, and broad pharmacy distribution.

Commercial factor	Vanrafia implication
Chronic treatment	Stability and packaging reliability matter
Oral tablet administration	Direct-compression and film-coating suppliers are relevant
Nephrology patient population	Tablet size and swallowability can influence adherence
Potential generic competition	Simple, scalable excipient systems are likely to be targeted
Multiple strengths	Color, coating, and weight differentiation reduce dispensing errors
Long-term use	Excipient impurity control and tolerability are important

A low-cost excipient system may be commercially attractive, but any change must preserve dissolution, bioequivalence, stability, and tablet identification across all approved strengths.

Key Takeaways

• Vanrafia is a lower-dose, once-daily sparsentan tablet for primary IgA nephropathy.
• Its main excipient challenge is low-dose content uniformity rather than high drug loading.
• Microcrystalline cellulose, disintegrants, binders, glidants, lubricants, and film coatings are the principal formulation categories.
• The strongest commercial opportunities are low-moisture excipients, co-processed direct-compression systems, low-peroxide binders, robust film coatings, and high-barrier packaging.
• Generic risk will depend on Orange Book patents, method-of-use claims, formulation claims, regulatory exclusivity, and Paragraph IV activity.
• Standard excipients are unlikely to provide durable protection alone. The commercial value lies in reproducible performance, regulatory documentation, and supply reliability.
• A complete exclusivity forecast requires the current FDA Orange Book record, patent-family review, and litigation docket analysis.

FAQs

Is Vanrafia an extended-release product?

Vanrafia is an oral film-coated tablet. The product is not generally positioned as an extended-release dosage form; its formulation strategy is based on immediate-release tablet performance and once-daily clinical dosing.

Can a generic Vanrafia use different excipients?

Yes. A generic applicant can generally use different inactive ingredients if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, stability, dissolution, and labeling requirements and does not infringe enforceable patents.

Are Vanrafia’s excipients proprietary?

The inactive ingredient categories may be conventional, but the specific grades, quantities, processing conditions, and supplier controls can be proprietary or protected as confidential CMC know-how.

What is the best 505(b)(2) opportunity for sparsentan?

The most plausible opportunities are alternative strengths, smaller tablets, orally disintegrating or sprinkle presentations, and formulations designed for patients with swallowing or adherence challenges, subject to clinical and regulatory requirements.

Does an excipient substitution automatically avoid Vanrafia formulation patents?

No. Patent claims may cover composition ranges, performance characteristics, dissolution profiles, or combinations of active ingredient and excipients. Substitution must be assessed against the complete patent family and claim language.

References

1. Travere Therapeutics, Inc. (2025). Vanrafia (sparsentan) prescribing information.
2. U.S. Food and Drug Administration. (2025a). Drugs@FDA: FDA-approved drugs database.
3. U.S. Food and Drug Administration. (2025b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2018). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and post-approval changes.
5. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptides.